Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia

A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulations in Patients With Nocturia

The purpose of this study is to investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia for a total duration of 14 weeks.

Inclusion Criteria:

• Male and female 50 years or older
• Nocturia of 6 or more months duration averaging greater than 2 nocturic episode per night

Exclusion Criteria:

• CHF
• Diabetis Insipidus
• Renal Insufficiency
• Hepatic Insufficiency
• Incontinence
• Illness requiring systemic steroids
• Malignancy within the past 5 years
• Sleep Apnea
• Nephrotic Syndrome
• Unexplained Pelvic Mass
• Urinary Bladder Neurological dysfunction
• Urinary Bladder Surgery or Radiotherapy
• Pregnant or Breast Feeding